Pandomedx
Davis, United States · Founded 2016
- Headquarters
- Davis, California
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
About
PandoMedx is developing Niclosamide (PDMX1001), a potent inhibitor of AR-V7, for treatment of advanced castration-resistant prostate cancer in combination with abiraterone. The company was founded by UC Davis cancer researchers and has received NIH/NCI SBIR grant funding. It holds an exclusive license from UC Davis for PDMX1001 and has conducted Phase I and Phase II clinical trials.
Summary
Pandomedx is a Biotech company based in Davis, United States, founded in 2016.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/pandomedx"><img src="https://indexed.vc/api/badge/company/pandomedx" alt="Pandomedx on Indexed.vc" width="260" height="76" /></a>